KALA BIO, Inc. (KALA)
(Delayed Data from NSDQ)
$5.90 USD
-0.16 (-2.64%)
Updated Aug 28, 2024 01:57 PM ET
After-Market: $5.96 +0.06 (1.02%) 7:40 PM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
Price, Consensus and EPS Surprise
KALA 5.90 -0.16(-2.64%)
Will KALA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KALA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KALA
KALA BIO (KALA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Does KALA BIO (KALA) Have the Potential to Rally 152.83% as Wall Street Analysts Expect?
KALA: What are Zacks experts saying now?
Zacks Private Portfolio Services
KALA BIO (KALA) Reports Q3 Loss, Misses Revenue Estimates
Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate
VYNE Gains on Preclinical Data for IPF Candidate
Other News for KALA
Oppenheimer 'encouraged' by Kala Pharmaceuticals trial progress
KALA BIO to Present at H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Buy Rating for Kala Pharmaceuticals Amidst Promising Clinical Trials and Strong Financials
Kala Pharmaceuticals price target lowered by $3 at H.C. Wainwright, here's why
KALA Stock Earnings: Kala Bio Beats EPS for Q2 2024